Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities

References

• Rastogi M, Pandey N, Shukla A, Singh SK. SARS coronavirus 2: from genome to infectome. Respir Res. 2020;21(1):318. doi:10.1186/s12931-020-01581-z
   PubMed Web of Science ®Google Scholar
• Pourrajab F, Zare-Khormizi MR, Sheikhha MH. Molecular basis for pathogenicity of human coronaviruses. Infect Drug Resist. 2020;13:2385–2405. doi:10.2147/IDR.S255156
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi:10.1002/jmv.25681
   PubMed Web of Science ®Google Scholar
• Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192. doi:10.1038/s41579-018-0118-9
   PubMed Web of Science ®Google Scholar
• Zhao L, Feng D, Ye R-Z, et al. Outbreak of COVID-19 and SARS in mainland China: a comparative study based on national surveillance data. BMJ Open. 2020;10(10):e043411. doi:10.1136/bmjopen-2020-043411
   PubMed Web of Science ®Google Scholar
• Liu DX, Liang JQ, Fung TS. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae). Ref Module Life Sci. 2020. doi:10.1016/B978-0-12-809633-8.21501-X
   Google Scholar
• Andersen KG, Rambaut AA, Lipkin WL, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020. doi:10.1038/s41591-020-0820-9
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Sahu P, Ranade AV, et al.Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020. doi:10.1136/postgradmedj-2020-138234
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374. doi:10.1038/s41577-020-0311-8
   PubMed Web of Science ®Google Scholar
• Tea F, Ospina Stella A, Aggarwal A, et al. SARS-CoV-2 neutralizing antibodies: longevity, breadth, and evasion by emerging viral variants. PLOS Med. 2021;18(7):e1003656. doi:10.1371/journal.pmed.1003656
   PubMed Web of Science ®Google Scholar
• Nalbant A, Kaya T, Varim C, Yaylaci S, Tamer A, Cinemre H. Can the neutrophil/lymphocyte ratio (NLR) have a role in the diagnosis of coronavirus 2019 disease (COVID-19)? Rev Assoc Med Bras. 2020;66(6):746–751. doi:10.1590/1806-9282.66.6.746
   PubMed Web of Science ®Google Scholar
• de Carvalho Lima EN, Diaz RS, Justo JF, Castilho Piqueira JR. Advances and perspectives in the use of carbon nanotubes in vaccine development. Int J Nanomedicine. 2021;16:5411–5435. doi:10.2147/IJN.S314308
   PubMed Web of Science ®Google Scholar
• Weiss C, Carriere M, Fusco L, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–6406. doi:10.1021/acsnano.0c03697
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–3174. doi:10.1016/j.vaccine.2014.04.016
   PubMed Web of Science ®Google Scholar
• Zheng B, Peng W, Guo M, et al. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chem Eng J. 2021;418:129392. doi:10.1016/j.cej.2021.129392
   PubMed Web of Science ®Google Scholar
• Song JW, Zhang C, Fan X, et al.Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11:1.
   PubMed Web of Science ®Google Scholar
• Yen Y-T, Liao F, Hsiao C-H, Kao C-L, Chen Y-C, Wu-Hsieh BA. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–2693. doi:10.1128/JVI.80.6.2684-2693.2006
   PubMed Web of Science ®Google Scholar
• Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi:10.1016/j.cytogfr.2020.06.001
   PubMed Web of Science ®Google Scholar
• Liu T, Feng M, Wen Z, He Y, Lin W, Zhang M. Comparison of the characteristics of cytokine storm and immune response induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 infections. J Inflamm Res. 2021;14:5475–5487. doi:10.2147/JIR.S329697
   PubMed Web of Science ®Google Scholar
• Dhar SK, Gujar S, Gujar S, Das M, Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155. doi:10.1016/j.heliyon.2021.e06155
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01708
   Web of Science ®Google Scholar
• Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75(7):1564–1581. doi:10.1111/all.14364
   PubMed Web of Science ®Google Scholar
• Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–362. doi:10.1038/s41577-020-0331-4
   PubMed Web of Science ®Google Scholar
• Chi Y, Ge Y, Wu B, et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J Infect Dis. 2020;222(5):746–754. doi:10.1093/infdis/jiaa363
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu T. CD4+T, CD8+T counts and severe COVID-19: a meta-analysis. J Infect. 2020;81(3):e82–e84. doi:10.1016/j.jinf.2020.06.036
   Web of Science ®Google Scholar
• Chen F, Zhang Y, Sucgang R, et al. Meta-analysis of host transcriptional responses to SARS-CoV-2 infection reveals their manifestation in human tumors. Sci Rep. 2021;11(1):2459. doi:10.1038/s41598-021-82221-4
   PubMed Web of Science ®Google Scholar
• Alnazawi M, Altaher A, Kandeel M. Comparative genomic analysis MERS CoV isolated from humans and camels with special reference to virus encoded helicase. Biol Pharm Bull. 2017;40(8):1289–1298. doi:10.1248/bpb.b17-00241
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254. doi:10.1038/nature12005
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang -H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643. doi:10.1038/s41591-020-1051-9
   PubMed Web of Science ®Google Scholar
• Chu H, Zhou J, Wong BH-Y, et al. Middle east respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis. 2016;213(6):904–914. doi:10.1093/infdis/jiv380
   PubMed Web of Science ®Google Scholar
• Lee S, Channappanavar R, Kanneganti T-D. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol. 2020;41(12):1083–1099. doi:10.1016/j.it.2020.10.005
   PubMed Web of Science ®Google Scholar
• de Sousa E, Ligeiro D, Lérias JR, et al. Mortality in COVID-19 disease patients: correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis. 2020;98:454–459. doi:10.1016/j.ijid.2020.07.016
   PubMed Web of Science ®Google Scholar
• Ahmed-Hassan H, Sisson B, Shukla RK, et al. Innate immune responses to highly pathogenic coronaviruses and other significant respiratory viral infections. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01979
   PubMed Web of Science ®Google Scholar
• Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976–988. doi:10.1016/j.csbj.2021.01.034
   PubMed Web of Science ®Google Scholar
• Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635–664. doi:10.1128/MMBR.69.4.635-664.2005
   PubMed Web of Science ®Google Scholar
• Kim Y-S, Aigerim A, Park U, et al. Sustained responses of neutralizing antibodies against middle east respiratory syndrome coronavirus (MERS-CoV) in recovered patients and their therapeutic applicability. Clin Infect Dis. 2021;73(3):e550–e558. doi:10.1093/cid/ciaa1345
   PubMed Web of Science ®Google Scholar
• Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17(6):621–630. doi:10.1038/s41423-020-0458-z
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xiang R, Huo S, et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther. 2021;6(1):233. doi:10.1038/s41392-021-00653-w
   PubMed Web of Science ®Google Scholar
• Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol. 2011;85(2):873–882. doi:10.1128/JVI.02062-10
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang C, Xu X, Xu W, Liu S. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149. doi:10.1038/s41401-020-0485-4
   PubMed Web of Science ®Google Scholar
• Pandey S, Kawai T, Akira S. Microbial sensing by toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb Perspect Biol. 2015;7(1):a016246. doi:10.1101/cshperspect.a016246
   Web of Science ®Google Scholar
• Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):84. doi:10.1038/s41392-020-0191-1
   PubMed Web of Science ®Google Scholar
• Zenarruzabeitia O, Astarloa-Pando G, Terrén I, et al. T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.655934
   Web of Science ®Google Scholar
• García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.01441
   Web of Science ®Google Scholar
• Alimardani V, Abolmaali SS, Tamaddon AM. Recent advances on nanotechnology-based strategies for prevention, diagnosis, and treatment of coronavirus infections. J Nanomater. 2021;2021:1–20. doi:10.1155/2021/9495126
   Web of Science ®Google Scholar
• Diaz RS, Vergara TRC. The COVID-19 second wave: a perspective to be explored. Brazilian J Infect Dis. 2021;25(1):101537. doi:10.1016/j.bjid.2020.101537
   PubMed Web of Science ®Google Scholar
• Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532. doi:10.1371/journal.pone.0245532
   PubMed Web of Science ®Google Scholar
• Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naïve to memory and everything in between. Adv Physiol Educ. 2013;37(4):273–283. doi:10.1152/advan.00066.2013
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-). 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
   PubMed Web of Science ®Google Scholar
• Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis. 2020;83:102437. doi:10.1016/j.bcmd.2020.102437
   PubMed Web of Science ®Google Scholar
• Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T‐cell responses and therapies against SARS‐CoV‐2 infection. Immunology. 2021;162(1):30–43. doi:10.1111/imm.13262
   PubMed Web of Science ®Google Scholar
• Farias de L, Fonseca EK, Strabelli DG, et al. Imaging findings in COVID-19 pneumonia. Clinics. 2020;75. doi:10.6061/clinics/2020/e2027
   Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844. doi:10.1038/s41591-020-0901-9
   PubMed Web of Science ®Google Scholar
• Callahan V, Hawks S, Crawford MA, et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. Viruses. 2021;13(6):1062. doi:10.3390/v13061062
   PubMed Web of Science ®Google Scholar
• Kasuga Y, Zhu B, Jang K-J, Yoo J-S. Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med. 2021;53(5):723–736. doi:10.1038/s12276-021-00602-1
   PubMed Web of Science ®Google Scholar
• Amor S, Fernández Blanco L, Baker D. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol. 2020;202(2):193–209. doi:10.1111/cei.13523
   PubMed Web of Science ®Google Scholar
• Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529–536. doi:10.1038/s41577-020-0402-6
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhuang M-W, Han L, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduct Target Ther. 2020;5(1):299. doi:10.1038/s41392-020-00438-7
   PubMed Web of Science ®Google Scholar
• Li J-Y, Liao C-H, Wang Q, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074. doi:10.1016/j.virusres.2020.198074
   PubMed Web of Science ®Google Scholar
• Schäfer A, Baric R. Epigenetic landscape during coronavirus infection. Pathogens. 2017;6(1):8. doi:10.3390/pathogens6010008
   PubMed Web of Science ®Google Scholar
• Mu J, Fang Y, Yang Q, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 2020;6(1):65. doi:10.1038/s41421-020-00208-3
   PubMed Web of Science ®Google Scholar
• Saifuddin N, Raziah AZ, Junizah AR. Carbon nanotubes: a review on structure and their interaction with proteins. J Chem. 2013;2013:1–18. doi:10.1155/2013/676815
   Web of Science ®Google Scholar
• Yang W, Thordarson P, Gooding JJ, Ringer SP, Braet F. Carbon nanotubes for biological and biomedical applications. Nanotechnology. 2007;18(41):412001. doi:10.1088/0957-4484/18/41/412001
   Web of Science ®Google Scholar
• Zhang M, Yang M, Morimoto T, et al. Size-dependent cell uptake of carbon nanotubes by macrophages: a comparative and quantitative study. Carbon N Y. 2018;127:93–101. doi:10.1016/j.carbon.2017.10.085
   Web of Science ®Google Scholar
• Dong J. Signaling pathways implicated in carbon nanotube-induced lung inflammation. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.552613
   Web of Science ®Google Scholar
• Orecchioni M, Bedognetti D, Sgarrella F, Marincola FM, Bianco A, Delogu L. Impact of carbon nanotubes and graphene on immune cells. J Transl Med. 2014;12(1):138. doi:10.1186/1479-5876-12-138
   PubMed Web of Science ®Google Scholar
• Singh S, Vardharajula S, Tiwari P, et al. Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine. 2012;5361. doi:10.2147/IJN.S35832
   PubMed Web of Science ®Google Scholar
• Thakur N, Thakur S, Chatterjee S, Das J, Sil PC. Nanoparticles as smart carriers for enhanced cancer immunotherapy. Front Chem. 2020;8. doi:10.3389/fchem.2020.597806
   PubMed Web of Science ®Google Scholar
• Huang Y, Zeng J. Recent development and applications of nanomaterials for cancer immunotherapy. Nanotechnol Rev. 2020;9(1):367–384. doi:10.1515/ntrev-2020-0027
   Web of Science ®Google Scholar
• Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother. 2014;10(9):2761–2774. doi:10.4161/hv.29589
   PubMed Web of Science ®Google Scholar
• Tîlmaciu C-M, Morris MC. Carbon nanotube biosensors. Front Chem. 2015;3. doi:10.3389/fchem.2015.00059
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Reddy R, Reddy N. A review on protein functionalized carbon nanotubes. J Appl Biomater Funct Mater. 2015;13(4). doi:10.5301/jabfm.5000231
   PubMed Web of Science ®Google Scholar
• Dong J, Ma Q. Type 2 immune mechanisms in carbon nanotube-induced lung fibrosis. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01120
   Web of Science ®Google Scholar
• Brown JM, Bai W, Raghavendra A, Podila R. Defect density in multiwalled carbon nanotubes influences ovalbumin adsorption and promotes macrophage activation and CD4+ T-cell proliferation. Int J Nanomedicine. 2016;11:4357–4371. doi:10.2147/IJN.S111029
   PubMed Web of Science ®Google Scholar
• Murphy FA, Schinwald A, Poland CA, Donaldson K. The mechanism of pleural inflammation by long carbon nanotubes: interaction of long fibres with macrophages stimulates them to amplify pro-inflammatory responses in mesothelial cells. Part Fibre Toxicol. 2012;9(1):8. doi:10.1186/1743-8977-9-8
   PubMed Web of Science ®Google Scholar
• Parra J, Abad-Somovilla A, Mercader JV, Taton TA, Abad-Fuentes A. Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens. J Control Release. 2013;170(2):242–251. doi:10.1016/j.jconrel.2013.05.019
   PubMed Web of Science ®Google Scholar
• Pondman KM, Salvador-Morales C, Paudyal B, Sim RB, Kishore U. Interactions of the innate immune system with carbon nanotubes. Nanoscale Horizons. 2017;2(4):174–186. doi:10.1039/C6NH00227G
   PubMed Web of Science ®Google Scholar
• Maruyama K, Haniu H, Saito N, et al. Endocytosis of multiwalled carbon nanotubes in bronchial epithelial and mesothelial cells. Biomed Res Int. 2015;2015:1–9. doi:10.1155/2015/793186
   Web of Science ®Google Scholar
• Zhou L, Forman HJ, Ge Y, Lunec J. Multi-walled carbon nanotubes: a cytotoxicity study in relation to functionalization, dose and dispersion. Toxicol Vitr. 2017;42:292–298. doi:10.1016/j.tiv.2017.04.027
   PubMed Web of Science ®Google Scholar
• Hamad I, Christy hunter A, Rutt KJ, Liu Z, Dai H, Moein Moghimi S. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol. 2008;45(14):3797–3803. doi:10.1016/j.molimm.2008.05.020
   PubMed Web of Science ®Google Scholar
• Allegri M, Perivoliotis DK, Bianchi MG, et al. Toxicity determinants of multi-walled carbon nanotubes: the relationship between functionalization and agglomeration. Toxicol Rep. 2016;3:230–243. doi:10.1016/j.toxrep.2016.01.011
   PubMed Web of Science ®Google Scholar
• Carty M, Guy C, Bowie AG. Detection of Viral Infections by Innate Immunity. Biochem Pharmacol. 2021;183:114316. doi:10.1016/j.bcp.2020.114316
   PubMed Web of Science ®Google Scholar
• Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020. doi:10.7759/cureus.7423
   Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–462. doi:10.1038/s41586-020-2550-z
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang B, Wan B, Yu L, Huang Q. Molecular dynamics study of carbon nanotube as a potential dual-functional inhibitor of HIV-1 integrase. Biochem Biophys Res Commun. 2013;436(4):650–654. doi:10.1016/j.bbrc.2013.06.009
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pacific J Allerg Immunol. 2020. doi:10.12932/AP-200220-0772
   Web of Science ®Google Scholar
• Chen B, Tian E-K, He B, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther. 2020;5(1):89. doi:10.1038/s41392-020-0190-2
   PubMed Web of Science ®Google Scholar
• Khang D, Lee YK, Choi E-J, Webster TJ, Kim S-H. Effect of the protein Corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomedicine. 2014;97. doi:10.2147/IJN.S72998
   Web of Science ®Google Scholar
• Aldinucci A, Turco A, Biagioli T, et al. Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale. Nano Lett. 2013;13(12):6098–6105. doi:10.1021/nl403396e
   PubMed Web of Science ®Google Scholar
• Yehia HN, Draper RK, Mikoryak C, et al. Single-walled carbon nanotube interactions with HeLa cells. J Nanobiotechnology. 2007;5(1):8. doi:10.1186/1477-3155-5-8
   PubMedGoogle Scholar
• Sierra S, Dávila M, Lowenstein PR, Domingo E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol. 2000;74(18):8316–8323. doi:10.1128/jvi.74.18.8316-8323.2000
   PubMed Web of Science ®Google Scholar
• Palomäki J, Välimäki E, Sund J, et al. Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano. 2011;5(9):6861–6870. doi:10.1021/nn200595c
   PubMed Web of Science ®Google Scholar
• Fadel TR, Steenblock ER, Stern E, et al. Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. 2008;8(7):2070–2076. doi:10.1021/nl080332i
   PubMed Web of Science ®Google Scholar
• Goldsmith BR, Brisson D, Lerner M. Researchers Attach Lyme Disease Antibodies to Nanotubes, Paving Way for Diagnostic Device. University of Pennsylvania; 2013:1–3.
   Google Scholar
• Hassan HA, Diebold SS, Smyth LA, Walters AA, Lombardi G, Al-Jamal KT. Application of carbon nanotubes in cancer vaccines: achievements, challenges and chances. J Control Release. 2019;297:79–90. doi:10.1016/j.jconrel.2019.01.017
   PubMed Web of Science ®Google Scholar
• Elhissi AMA, Ahmed W, Hassan IU, Dhanak VR, D’Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv. 2012;2012:1–10. doi:10.1155/2012/837327
   Google Scholar
• Son KH, Hong JH, Lee JW. Carbon nanotubes as cancer therapeutic carriers and mediators. Int J Nanomedicine. 2016;11:5163–5185. doi:10.2147/IJN.S112660
   PubMed Web of Science ®Google Scholar
• Adesina SK, Akala EO. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol Pharm. 2015;12(12):4175–4187. doi:10.1021/acs.molpharmaceut.5b00335
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DL, Weiss M, Naumov A, Bartholomeusz G, Weisman RB, Gliko O. Carbon nanotubes: solution for the therapeutic delivery of siRNA? Materials (Basel). 2012;5(12):278–301. doi:10.3390/ma5020278
   PubMed Web of Science ®Google Scholar
• Karchemski F, Zucker D, Barenholz Y, Regev O. Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. J Control Release. 2012;160(2):339–345. doi:10.1016/j.jconrel.2011.12.037
   PubMed Web of Science ®Google Scholar
• Hassan HA, Smyth L, Wang JT-W, et al. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials. 2016;104:310–322. doi:10.1016/j.biomaterials.2016.07.005
   PubMed Web of Science ®Google Scholar
• Wang X, Ren J, Qu X. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. ChemMedChem. 2008;3(6):940–945. doi:10.1002/cmdc.200700329
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Hassan HA, Smyth L, Rubio N, et al. Carbon nanotubes’ surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. J Control Release. 2016;225:205–216. doi:10.1016/j.jconrel.2016.01.030
   PubMed Web of Science ®Google Scholar
• Tkach AV, Shurin GV, Shurin MR, et al. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS Nano. 2011;5(7):5755–5762. doi:10.1021/nn2014479
   PubMed Web of Science ®Google Scholar
• Lauster D, Klenk S, Ludwig K, et al. Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry. Nat Nanotechnol. 2020;15(5):373–379. doi:10.1038/s41565-020-0660-2
   PubMed Web of Science ®Google Scholar
• Vijayan M, Uthaman P. Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics. 2019;11(10):534. doi:10.3390/pharmaceutics11100534
   PubMed Web of Science ®Google Scholar
• Meher BR, Wang Y. Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism. J Mol Graph Model. 2012;38:430–445. doi:10.1016/j.jmgm.2012.10.001
   PubMed Web of Science ®Google Scholar
• Pereyra F, Heckerman D, Carlson JM, et al. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. J Virol. 2014;88(22):12937–12948. doi:10.1128/JVI.01004-14
   PubMed Web of Science ®Google Scholar
• Hunt PW. Th17, gut, and HIV: therapeutic implications. Curr Opin HIV AIDS. 2010;5(2):189–193. doi:10.1097/COH.0b013e32833647d9
   PubMed Web of Science ®Google Scholar
• Vela Ramirez JE, Roychoudhury R, Habte HH, Cho MW, Pohl NLB, Narasimhan B. Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells. J Biomater Sci Polym Ed. 2014;25(13):1387–1406. doi:10.1080/09205063.2014.940243
   PubMed Web of Science ®Google Scholar
• Nagy LH, Grishina I, Macal M, et al. Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal lactobacillus. PLoS One. 2013;8:8. doi:10.1371/journal.pone.0072789
   Web of Science ®Google Scholar
• Pantarotto D, Partidos CD, Hoebeke J, et al. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol. 2003;10(10):961–966. doi:10.1016/j.chembiol.2003.09.011
   PubMedGoogle Scholar
• Villa CH, Dao T, Ahearn I, et al. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano. 2011;5(7):5300–5311. doi:10.1021/nn200182x
   PubMed Web of Science ®Google Scholar
• Feng M, Bell DR, Zhou R. Propensity of a single-walled carbon nanotube-peptide to mimic a KK10 peptide in an HLA-TCR complex. J Chem Phys. 2017;147(22):225101. doi:10.1063/1.4996374
   PubMed Web of Science ®Google Scholar
• Olsen LR, Zhang GL, Keskin DB, Reinherz EL, Brusic V. Conservation analysis of dengue virus t-cell epitope-based vaccine candidates using peptide block entropy. Front Immunol. 2011;2:(DEC):1–15. doi:10.3389/fimmu.2011.00069
   PubMed Web of Science ®Google Scholar
• Versiani AF, Astigarraga RG, Rocha ESO, et al. Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice. J Nanobiotechnology. 2017;15(1):26. doi:10.1186/s12951-017-0259-4
   PubMed Web of Science ®Google Scholar
• Ménard-Moyon C, Kostarelos K, Prato M, Bianco A. Functionalized carbon nanotubes for probing and modulating molecular functions. Chem Biol. 2010;17(2):107–115. doi:10.1016/j.chembiol.2010.01.009
   PubMedGoogle Scholar
• Zhao Z, Zhang C, Jia Y-J, et al. Immersion vaccination of Mandarin fish Siniperca chuatsi against infectious spleen and kidney necrosis virus with a SWCNTs-based subunit vaccine. Fish Shellfish Immunol. 2019;92:133–140. doi:10.1016/j.fsi.2019.06.001
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang C, Lin Q, et al. Single-walled carbon nanotubes as delivery vehicles enhance the immunoprotective effect of an immersion DNA vaccine against infectious spleen and kidney necrosis virus in mandarin fish. Fish Shellfish Immunol. 2020;97:432–439. doi:10.1016/j.fsi.2019.12.072
   PubMed Web of Science ®Google Scholar
• Jia Y-J, Guo Z-R, Ma R, et al. Immune efficacy of carbon nanotubes recombinant subunit vaccine against largemouth bass ulcerative syndrome virus. Fish Shellfish Immunol. 2020;100:317–323. doi:10.1016/j.fsi.2020.03.025
   PubMed Web of Science ®Google Scholar
• Hu F, Li Y, Wang Q, et al. Carbon nanotube-based DNA vaccine against koi herpesvirus given by intramuscular injection. Fish Shellfish Immunol. 2020;98:810–818. doi:10.1016/j.fsi.2019.11.035
   PubMed Web of Science ®Google Scholar
• Sano M, Ito T, Kurita J, et al. First detection of Koi Herpesvirus in cultured common Carp Cyprinus carpio in Japan. Fish Pathol. 2004;39(3):165–167. doi:10.3147/jsfp.39.165
   Web of Science ®Google Scholar
• Zhu B, Liu G-L, Gong Y-X, Ling F, Song L-S, Wang G-X. Single-walled carbon nanotubes as candidate recombinant subunit vaccine carrier for immunization of grass carp against grass carp reovirus. Fish Shellfish Immunol. 2014;41(2):279–293. doi:10.1016/j.fsi.2014.09.014
   PubMed Web of Science ®Google Scholar
• Qiu D-K, Jia Y-J, Gong Y-M, Zheng -Y-Y, Wang G-X, Zhu B. Optimizing the immunization procedure of single-walled carbon nanotubes based vaccine against grass carp reovirus for grass carp. Aquaculture. 2021;533:736152. doi:10.1016/j.aquaculture.2020.736152
   Web of Science ®Google Scholar
• Su H, Su J. Cyprinid viral diseases and vaccine development. Fish Shellfish Immunol. 2018;83:84–95. doi:10.1016/j.fsi.2018.09.003
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu G-L, Li D-L, Ling F, Zhu B, Wang G-X. The protective immunity against grass carp reovirus in grass carp induced by a DNA vaccination using single-walled carbon nanotubes as delivery vehicles. Fish Shellfish Immunol. 2015;47(2):732–742. doi:10.1016/j.fsi.2015.10.029
   PubMed Web of Science ®Google Scholar
• Costa PM, Bourgognon M, Wang JT-W, Al-Jamal KT. Functionalised carbon nanotubes: from intracellular uptake and cell-related toxicity to systemic brain delivery. J Control Release. 2016;241:200–219. doi:10.1016/j.jconrel.2016.09.033
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Chattopadhyay D, Kappel BJ, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med. 2007;48(7):1180–1189. doi:10.2967/jnumed.106.039131
   PubMed Web of Science ®Google Scholar
• Meng J, Meng J, Duan J, et al. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small. 2008;4(9):1364–1370. doi:10.1002/smll.200701059
   PubMed Web of Science ®Google Scholar
• Gannon CJ, Cherukuri P, Yakobson BI, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer. 2007;110(12):2654–2665. doi:10.1002/cncr.23155
   PubMed Web of Science ®Google Scholar
• Xu H, Meng J, Kong H. What are carbon nanotubes’ roles in anti-tumor therapies? Sci China Chem. 2010;53(11):2250–2256. doi:10.1007/s11426-010-4117-6
   Web of Science ®Google Scholar
• Battigelli A, Ménard-Moyon C, Bianco A. Carbon nanomaterials as new tools for immunotherapeutic applications. J Mater Chem B. 2014;2(37):6144–6156. doi:10.1039/C4TB00563E
   PubMed Web of Science ®Google Scholar
• Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006;6(7):1522–1528. doi:10.1021/nl061160x
   PubMed Web of Science ®Google Scholar
• Yeh J-M, Huang K-Y, Lin S-Y, Wu -Y-Y, Huang -C-C, Liou S-J. Noncovalent interaction between gold nanoparticles and multiwalled carbon nanotubes via an intermediatory. J Nanotechnol. 2009;2009:1–7. doi:10.1155/2009/217469
   Google Scholar
• Hu X, Zhang Y, Ding T, Liu J, Zhao H. Multifunctional gold nanoparticles: a novel nanomaterial for various medical applications and biological activities. Front Bioeng Biotechnol. 2020;8. doi:10.3389/fbioe.2020.00990
   Web of Science ®Google Scholar
• Rance GA, Khlobystov AN. Interactions of carbon nanotubes and gold nanoparticles: the effects of solvent dielectric constant and temperature on controlled assembly of superstructures. Dalt Trans. 2014;43(20):7400. doi:10.1039/c3dt53372g
   PubMed Web of Science ®Google Scholar
• Kim H, Park M, Hwang J, et al. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sensors. 2019;4(5):1306–1312. doi:10.1021/acssensors.9b00175
   PubMed Web of Science ®Google Scholar
• Pramanik A, Gao Y, Patibandla S, et al. The rapid diagnosis and effective inhibition of coronavirus using spike antibody attached gold nanoparticles. Nanoscale Adv. 2021;3(6):1588–1596. doi:10.1039/D0NA01007C
   PubMed Web of Science ®Google Scholar
• Mehranfar A, Izadyar M. Theoretical design of functionalized gold nanoparticles as antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Phys Chem Lett. 2020;11(24):10284–10289. doi:10.1021/acs.jpclett.0c02677
   PubMed Web of Science ®Google Scholar
• Tharayil A, Rajakumari R, Kumar A, Choudhary MD, Palit P, Thomas S. New insights into application of nanoparticles in the diagnosis and screening of novel coronavirus (SARS-CoV-2). Emergent Mater. 2021;4(1):101–117. doi:10.1007/s42247-021-00182-w
   PubMedGoogle Scholar
• Paradowska E, Studzińska M, Jabłońska A, et al. Antiviral effect of nonfunctionalized gold nanoparticles against herpes simplex virus type-1 (HSV-1) and possible contribution of near-field interaction mechanism. Molecules. 2021;26(19):5960. doi:10.3390/molecules26195960
   PubMed Web of Science ®Google Scholar
• Lew TTS, Aung KMM, Ow SY, et al. Epitope-functionalized gold nanoparticles for rapid and selective detection of SARS-CoV-2 IgG antibodies. ACS Nano. 2021;15(7):12286–12297. doi:10.1021/acsnano.1c04091
   PubMed Web of Science ®Google Scholar
• Medhi R, Srinoi P, Ngo N, Tran H-V, Lee TR. Nanoparticle-Based Strategies to Combat COVID-19. ACS Appl Nano Mater. 2020;3(9):8557–8580. doi:10.1021/acsanm.0c01978
   PubMed Web of Science ®Google Scholar
• Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. Silver nanoparticles as potential antiviral agents. Molecules. 2011;16(10):8894–8918. doi:10.3390/molecules16108894
   PubMed Web of Science ®Google Scholar
• Lee B, Lee MJ, Yun SJ, Kim K, Choi I-H, Park S. Silver nanoparticles induce reactive oxygen species-mediated cell cycle delay and synergistic cytotoxicity with 3-bromopyruvate in Candida albicans, but not in Saccharomyces cerevisiae. Int J Nanomedicine. 2019;14:4801–4816. doi:10.2147/IJN.S205736
   PubMed Web of Science ®Google Scholar
• Quinteros MA, Cano Aristizábal V, Dalmasso PR, Paraje MG, Páez PL. Oxidative stress generation of silver nanoparticles in three bacterial genera and its relationship with the antimicrobial activity. Toxicol Vitr. 2016;36:216–223. doi:10.1016/j.tiv.2016.08.007
   PubMed Web of Science ®Google Scholar
• Khodashenas B, Ghorbani HR. Synthesis of silver nanoparticles with different shapes. Arab J Chem. 2019;12(8):1823–1838. doi:10.1016/j.arabjc.2014.12.014
   Web of Science ®Google Scholar
• Allawadhi P, Singh V, Khurana A, et al. Silver nanoparticle based multifunctional approach for combating COVID-19. Sensors Int. 2021;2:100101. doi:10.1016/j.sintl.2021.100101
   PubMedGoogle Scholar
• Parnsamut C, Brimson S. Effects of silver nanoparticles and gold nanoparticles on IL-2, IL-6, and TNF-α production via MAPK pathway in leukemic cell lines. Genet Mol Res. 2015;14(2):3650–3668. doi:10.4238/2015.April.17.15
   PubMed Web of Science ®Google Scholar
• Borowik A, Butowska K, Konkel K, et al. The impact of surface functionalization on the biophysical properties of silver nanoparticles. Nanomaterials. 2019;9(7):973. doi:10.3390/nano9070973
   Web of Science ®Google Scholar
• Di Pietro P, Strano G, Zuccarello L, Satriano C. Gold and silver nanoparticles for applications in theranostics. Curr Top Med Chem. 2016;16(27):3069–3102. doi:10.2174/1568026616666160715163346
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang D, Alocilja EC, Chakrabartty S. Biomolecules detection using a silver-enhanced gold nanoparticle-based biochip. Nanoscale Res Lett. 2010;5(3):533–538. doi:10.1007/s11671-010-9542-0
   PubMed Web of Science ®Google Scholar
• Pilaquinga F, Morey J, Torres M, Seqqat R, Piña de Las N. Silver nanoparticles as a potential treatment against SARS‐CoV ‐2: a review. WIREs Nanomed Nanobiotechnol. 2021;13(5). doi:10.1002/wnan.1707
   Google Scholar
• Bruna T, Maldonado-Bravo F, Jara P, Caro N. Silver nanoparticles and their antibacterial applications. Int J Mol Sci. 2021;22(13):7202. doi:10.3390/ijms22137202
   PubMed Web of Science ®Google Scholar
• Chue-Gonçalves M, Pereira GN, Faccin-Galhardi LC, Kobayashi RKT, Nakazato G. Metal nanoparticles against viruses: possibilities to fight SARS-CoV-2. Nanomaterials. 2021;11(11):3118. doi:10.3390/nano11113118
   Web of Science ®Google Scholar
• Niemiec SM, Hilton SA, Wallbank A, et al. Lung function improves after delayed treatment with CNP-miR146a following acute lung injury. Nanomed Nanotechnol Biol Med. 2021;102498. doi:10.1016/j.nano.2021.102498
   PubMed Web of Science ®Google Scholar
• Allawadhi P, Khurana A, Allwadhi S, Joshi K, Packirisamy G, Bharani KK. Nanoceria as a possible agent for the management of COVID-19. Nano Today. 2020;35:100982. doi:10.1016/j.nantod.2020.100982
   PubMed Web of Science ®Google Scholar
• Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673. doi:10.1016/j.micpath.2020.104673
   PubMed Web of Science ®Google Scholar
• Khurana A, Anchi P, Allawadhi P, et al. Superoxide dismutase mimetic nanoceria restrains cerulein induced acute pancreatitis. Nanomedicine. 2019;14(14):1805–1825. doi:10.2217/nnm-2018-0318
   PubMed Web of Science ®Google Scholar
• Khurana I, Allawadhi P, Khurana A, et al. Can bilirubin nanomedicine become a hope for the management of COVID-19? Med Hypotheses. 2021;149:110534. doi:10.1016/j.mehy.2021.110534
   PubMed Web of Science ®Google Scholar
• Rasmi Y, Saloua KS, Nemati M, Choi JR. Recent progress in nanotechnology for COVID-19 prevention, diagnostics and treatment. Nanomaterials. 2021;11(7):1788. doi:10.3390/nano11071788
   Web of Science ®Google Scholar
• Niemiec SM, Hilton SA, Wallbank A, et al. Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury. Nanomed Nanotechnol Biol Med. 2021;34:102388. doi:10.1016/j.nano.2021.102388
   PubMed Web of Science ®Google Scholar
• Jagaran K, Singh M. Nanomedicine for COVID-19: potential of Copper Nanoparticles. Biointerface Res Appl Chem. 2020;11(3):10716–10728. doi:10.33263/BRIAC113.1071610728
   Web of Science ®Google Scholar
• Wang ZY, He N, Wang YJ, Zhang J. Effects of copper on organisms: a review. Adv Mater Res. 2013;726–731:340–343. doi:10.4028/www.scientific.net/AMR.726-731.340
   Google Scholar
• Tortella GR, Pieretti JC, Rubilar O, et al. Silver, copper and copper oxide nanoparticles in the fight against human viruses: progress and perspectives. Crit Rev Biotechnol. 2021;1–19. doi:10.1080/07388551.2021.1939260
   Web of Science ®Google Scholar
• Tyavambiza C, Elbagory AM, Madiehe AM, Meyer M, Meyer S. The antimicrobial and anti-inflammatory effects of silver nanoparticles synthesised from cotyledon orbiculata aqueous extract. Nanomaterials. 2021;11(5):1343. doi:10.3390/nano11051343
   Web of Science ®Google Scholar
• Bondarenko OM, Sihtmäe M, Kuzmičiova J, Ragelienė L, Kahru A, Daugelavičius R. Plasma membrane is the target of rapid antibacterial action of silver nanoparticles in Escherichia coli and Pseudomonas aeruginosa. Int J Nanomedicine. 2018;13:6779–6790. doi:10.2147/IJN.S177163
   PubMed Web of Science ®Google Scholar
• Govind V, Bharadwaj S, Sai Ganesh MR, et al. Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review. BioMetals. 2021;34(6):1217–1235. doi:10.1007/s10534-021-00339-4
   PubMed Web of Science ®Google Scholar
• Peng Z, Liu X, Zhang W, et al. Advances in the application, toxicity and degradation of carbon nanomaterials in environment: a review. Environ Int. 2020;134:105298. doi:10.1016/j.envint.2019.105298
   PubMed Web of Science ®Google Scholar
• Vlasova II, Vakhrusheva TV, Sokolov AV, et al. PEGylated single-walled carbon nanotubes activate neutrophils to increase production of hypochlorous acid, the oxidant capable of degrading nanotubes. Toxicol Appl Pharmacol. 2012;264(1):131–142. doi:10.1016/j.taap.2012.07.027
   PubMed Web of Science ®Google Scholar
• Shvedova AA, Pietroiusti A, Fadeel B, Kagan VE. Mechanisms of carbon nanotube-induced toxicity: focus on oxidative stress. Toxicol Appl Pharmacol. 2012;261(2):121–133. doi:10.1016/j.taap.2012.03.023
   PubMed Web of Science ®Google Scholar
• Sobajima A, Haniu H, Nomura H, et al. Organ accumulation and carcinogenicity of highly dispersed multi-walled carbon nanotubes administered intravenously in transgenic rasH2 mice. Int J Nanomedicine. 2019;14:6465–6480. doi:10.2147/IJN.S208129
   PubMed Web of Science ®Google Scholar
• Magrez A, Kasas S, Salicio V, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett. 2006;6(6):1121–1125. doi:10.1021/nl060162e
   PubMed Web of Science ®Google Scholar
• Vlasova II, Kapralov AA, Michael ZP, et al. Enzymatic oxidative biodegradation of nanoparticles: mechanisms, significance and applications. Toxicol Appl Pharmacol. 2016;299:58–69. doi:10.1016/j.taap.2016.01.002
   PubMed Web of Science ®Google Scholar
• Allen BL, Kichambare PD, Gou P, et al. Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. Nano Lett. 2008;8(11):3899–3903. doi:10.1021/nl802315h
   PubMed Web of Science ®Google Scholar
• Kotchey GP, Zhao Y, Kagan VE, Star A. Peroxidase-mediated biodegradation of carbon nanotubes in vitro and in vivo. Adv Drug Deliv Rev. 2013;65(15):1921–1932. doi:10.1016/j.addr.2013.07.007
   PubMed Web of Science ®Google Scholar
• Kotchey GP, Gaugler JA, Kapralov AA, Kagan VE, Star A. Effect of antioxidants on enzyme-catalysed biodegradation of carbon nanotubes. J Mater Chem B. 2013;1(3):302–309. doi:10.1039/C2TB00047D
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang M. Biodegradation of carbon nanotubes by macrophages. Front Mater. 2019;6. doi:10.3389/fmats.2019.00225
   Web of Science ®Google Scholar
• Yang M, Zhang M, Nakajima H, Yudasaka M, Iijima S, Okazaki T. Time-dependent degradation of carbon nanotubes correlates with decreased reactive oxygen species generation in macrophages. Int J Nanomedicine. 2019;14:2797–2807. doi:10.2147/IJN.S199187
   PubMed Web of Science ®Google Scholar
• Hou J, Wan B, Yang Y, Ren X-M, Guo L-H, Liu J-F. Biodegradation of single-walled carbon nanotubes in macrophages through respiratory burst modulation. Int J Mol Sci. 2016;17(3):409. doi:10.3390/ijms17030409
   PubMed Web of Science ®Google Scholar
• Zhu W, von Dem Bussche A, Yi X, et al. Nanomechanical mechanism for lipid bilayer damage induced by carbon nanotubes confined in intracellular vesicles. Proc Natl Acad Sci. 2016;113(44):12374–12379. doi:10.1073/pnas.1605030113
   PubMed Web of Science ®Google Scholar
• Khurana A, Allawadhi P, Khurana I, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021;38:101142. doi:10.1016/j.nantod.2021.101142
   PubMed Web of Science ®Google Scholar
• Fraix A, Kandoth N, Manet I, et al. An engineered nanoplatform for bimodal anticancer phototherapy with dual-color fluorescence detection of sensitizers. Chem Commun (Camb). 2013;49(40):4459–4461. doi:10.1039/c3cc40714d
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487–1490. doi:10.1164/rccm.200504-613PP
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416. doi:10.1016/S0140-6736(21)02183-8
   PubMed Web of Science ®Google Scholar
• Jazayeri SD, Lim HX, Shameli K, Yeap SK, Poh CL. Nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.682286
   PubMed Web of Science ®Google Scholar
• Nature Editorials. Nanotechnology versus coronavirus. Nat Nanotechnol. 2020;15(8):617. doi:10.1038/s41565-020-0757-7
   PubMed Web of Science ®Google Scholar
• Fadel TR, Fahmy TM. Immunotherapy applications of carbon nanotubes: from design to safe applications. Trends Biotechnol. 2014;32(4):198–209. doi:10.1016/j.tibtech.2014.02.005
   PubMed Web of Science ®Google Scholar
• Kim H, Kim EH, Kwak G, Chi S-G, Kim SH, Yang Y. Exosomes: cell-derived nanoplatforms for the delivery of cancer therapeutics. Int J Mol Sci. 2020;22(1):14. doi:10.3390/ijms22010014
   PubMed Web of Science ®Google Scholar
• Heo MB, Lim YT. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials. 2014;35(1):590–600. doi:10.1016/j.biomaterials.2013.10.009
   PubMed Web of Science ®Google Scholar
• Kraegeloh A, Suarez-Merino B, Sluijters T, Micheletti C. Implementation of safe-by-design for nanomaterial development and safe innovation: why we need a comprehensive approach. Nanomaterials. 2018;8(4):239. doi:10.3390/nano8040239
   Web of Science ®Google Scholar
• Rai M, Bonde S, Yadav A, et al. Nanotechnology as a shield against COVID-19: current advancement and limitations. Viruses. 2021;13(7):1224. doi:10.3390/v13071224
   PubMed Web of Science ®Google Scholar
• Himaja AL, Karthik PS, Singh SP. Carbon dots: the newest member of the carbon nanomaterials family. Chem Rec. 2015;15(3):595–615. doi:10.1002/tcr.201402090
   PubMed Web of Science ®Google Scholar
• Atabaev T. Doped carbon dots for sensing and bioimaging applications: a minireview. Nanomaterials. 2018;8(5):342. doi:10.3390/nano8050342
   Web of Science ®Google Scholar
• Kotta S, Aldawsari HM, Badr-Eldin SM, et al. Exploring the Potential of Carbon Dots to Combat COVID-19. Front Mol Biosci. 2020;7. doi:10.3389/fmolb.2020.616575
   Web of Science ®Google Scholar
• Serrano-Aroca Á, Takayama K, Tuñón-Molina A, et al. Carbon-based nanomaterials: promising antiviral agents to combat COVID-19 in the microbial-resistant era. ACS Nano. 2021;15(5):8069–8086. doi:10.1021/acsnano.1c00629
   PubMed Web of Science ®Google Scholar
• Liang L, Ahamed A, Ge L, Fu X, Lisak G. Advances in antiviral material development. Chempluschem. 2020;85(9):2105–2128. doi:10.1002/cplu.202000460
   PubMed Web of Science ®Google Scholar
• Liu H, Chen J, Qiao S, Zhang W. Carbon-based nanomaterials for bone and cartilage regeneration: a review. ACS Biomater Sci Eng. 2021;7(10):4718–4735. doi:10.1021/acsbiomaterials.1c00759
   PubMed Web of Science ®Google Scholar
• Ehtesabi H. Application of carbon nanomaterials in human virus detection. J Sci Adv Mater Devices. 2020;5(4):436–450. doi:10.1016/j.jsamd.2020.09.005
   Google Scholar
• Innocenzi P, Stagi L. Carbon-based antiviral nanomaterials: graphene, C-dots, and fullerenes. A perspective. Chem Sci. 2020;11(26):6606–6622. doi:10.1039/D0SC02658A
   PubMed Web of Science ®Google Scholar
• Chen M, Sun Y, Liang J, et al. Understanding the influence of carbon nanomaterials on microbial communities. Environ Int. 2019;126:690–698. doi:10.1016/j.envint.2019.02.005
   PubMed Web of Science ®Google Scholar
• Wang F-T, Wang L-N, Xu J, Huang K-J, Wu X. Synthesis and modification of carbon dots for advanced biosensing application. Analyst. 2021;146(14):4418–4435. doi:10.1039/D1AN00466B
   PubMed Web of Science ®Google Scholar
• Kalkal A, Allawadhi P, Pradhan R, Khurana A, Bharani KK, Packirisamy G. Allium sativum derived carbon dots as a potential theranostic agent to combat the COVID-19 crisis. Sensors Int. 2021;2:100102. doi:10.1016/j.sintl.2021.100102
   PubMedGoogle Scholar
• Ahmadian-Fard-Fini S, Ghanbari D, Salavati-Niasari M. Photoluminescence carbon dot as a sensor for detecting of Pseudomonas aeruginosa bacteria: hydrothermal synthesis of magnetic hollow NiFe2O4-carbon dots nanocomposite material. Compos Part B Eng. 2019;161:564–577. doi:10.1016/j.compositesb.2018.12.131
   Web of Science ®Google Scholar
• Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. 2020;5(49):eabd7114. doi:10.1126/sciimmunol.abd7114
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang ML, Chien CS, et al.Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Front Immunol. 2020;11:1022.
   PubMed Web of Science ®Google Scholar